NCT06393452View on ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Androgenetic Alopecia
Interventions
DRUG

PP405 0.05% Topical Gel

PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC)

DRUG

PP405 Topical Vehicle Gel

PP405 Vehicle = placebo

Trial Locations (8)

23502

Virginia Clinical Research, Inc., Norfolk

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

55112

Minnesota Clinical Study Center, New Brighton

77479

Stride Clinical Research LLC, Sugar Land

78759

DermResearch, Austin

84095

Jordan Valley Dermatology Center, South Jordan

91320

Clinical Trials Research Institute, Thousand Oaks

92024

California Dermatology & Clinical Research Institute, Encinitas

Sponsors
All Listed Sponsors
lead

Pelage Pharmaceuticals, Inc.

INDUSTRY

NCT06393452 - Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA | Biotech Hunter | Biotech Hunter